Neuroleptic malignant syndrome with the addition of aripiprazole to olanzapine

American Journal of Psychiatry

Volumn 165, Issue 11, 2008, Pages 1488-1489

  Marshall, Phillip B ^a   Mellman, Thomas A ^a   Nguyen, Shana Xuanlan C ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ARIPIPRAZOLE; BENZATROPINE; BROMOCRIPTINE; DANTROLENE; LORAZEPAM; OLANZAPINE;

ADULT; AGGRESSION; CASE REPORT; CLINICAL FEATURE; COLD SWEAT; DRUG DOSE INCREASE; DRUG EFFECT; DRUG SAFETY; HUMAN; INSOMNIA; IRRITABILITY; LETTER; MALE; NEUROLEPTIC MALIGNANT SYNDROME; PAIN; PRIORITY JOURNAL; RIGIDITY; RISK FACTOR; SYMPTOM; WEAKNESS;

ADULT; AGGRESSION; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BENZTROPINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; HUMANS; MALE; MENTAL RETARDATION; NEUROLEPTIC MALIGNANT SYNDROME; NEUROLOGIC EXAMINATION; PIPERAZINES; QUINOLONES; RISK FACTORS;

EID: 55749086665     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2008.07121972     Document Type: Letter

References (5)

1. Stahl SM: Essential Psychopharmacology, 2nd ed. New York, Cambridge University Press, 2004, pp 401-458
2. Sankaranarayanan J, Puumala SE: Antipsychotic use at adult ambulatory care visits by patients with mental health disorders in the United States, 1996-2003: national estimates and associated factors. Clin Therapeutics 2007; 29:723-741
3. Ananth J, Parameswaran S, Gunatilake S, Burgoyne K, Sidhom T: Neuroleptic malignant syndrome and atypical antipsychotic drugs. J Clin Psychiatry 2004 65:464-470
4. Srephichit S, Sanchez R, Bourgeois JA: Neuroleptic malignant syndrome and aripiprazole in an antipsychotic-naïve patient. J Clin Psychopharmacol 2006; 26:94-95
5. Tanii H: Studies of risk factors and preventive care for neuroleptic malignant syndrome. Nihon Shinkei Seishin Yakurigaku Zasshi 2006; 26:177-181